TheraSphere

Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.

Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC)

Building Evidence for Ablative Internal Radiation Therapy in Localized HCC Beyond the Up-To-7 Criteria

TheraSphere for the Treatment of Unresectable Hepatocellular Carcinoma

Transarterial Radioembolization (TARE) in COlorectal MEtastasis of Liver

TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma

Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer

Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer

Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery

Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer

TheraSphere & Treatment of Unresectable Primary or Unresectable Secondary Liver Cancer

Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein

RadioEmbolization for the ADvancement of Y90 Glass Microspheres Registry

A TheraSphere® Advanced Dosimetry Retrospective Global Study in HCC

A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®

A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma

Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease

TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis